Pieris Pharmaceuticals Inc (PIRS.OQ)
26 Apr 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|62||2017||Chairman of the Board|
|39||2014||President, Chief Executive Officer, Director|
|50||2017||Acting Chief Financial Officer|
|2016||Senior Vice President, Chief Business Officer|
|54||2015||Senior Vice President and Chief Development Officer|
- BRIEF-Pieris Pharmaceuticals Prices Public Offering Of 5.50 Mln Common Shares At $8/Share
- BRIEF-Seattle Genetics And Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration
- BRIEF-Pieris Pharmaceuticals And Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration
- BRIEF-Pieris Pharma Doses First Subjects In Phase I Study Of PRS-060
- BRIEF-Pieris Pharma Received Clearance to Initiate Its First-In-Human Study In Australia For PRS-060/AZD1402